| Metric | Current Period | Same Period Last Year | YoY |
|---|---|---|---|
| Revenue | ¥42.0B | ¥40.5B | +3.7% |
| Operating Income | ¥6.0B | ¥6.7B | -11.3% |
| Ordinary Income | ¥6.2B | ¥6.8B | -8.0% |
| Net Income | ¥4.5B | ¥4.9B | -8.8% |
| ROE | 6.3% | 7.2% | - |
FY2026 Q3 results were Revenue ¥42.0B (YoY +¥1.5B +3.7%), Operating Income ¥6.0B (YoY -¥0.8B -11.3%), Ordinary Income ¥6.2B (YoY -¥0.5B -8.0%), and Net Income ¥4.5B (YoY -¥0.4B -8.8%). While revenue is on an upward trend, higher selling, general and administrative expenses (SG&A) caused Operating Income to fall below the prior-year level; at the Ordinary Income stage, non-operating income contributed to narrowing the decline. The Gross Profit Margin remained high at 47.4%, but the rising SG&A ratio pressured profitability. Full-year guidance calls for Revenue of ¥55.0B (YoY +3.7%), Operating Income of ¥8.5B (YoY +3.2%), and Net Income of ¥6.0B (YoY -6.4%), with a year-end dividend of ¥32 (Payout Ratio approximately 35.8%).
[Profitability] ROE 6.3% (calculated as Net Profit Margin 10.6% × Total Asset Turnover 0.468 × Financial Leverage 1.26x), Operating Margin 14.2% (down -2.3pt from 16.5% a year earlier), Net Profit Margin 10.6% (down -1.6pt from 12.2% a year earlier). The Gross Profit Margin remains high at 47.4%, but rising SG&A is compressing margins. [Cash Quality] Cash and deposits ¥31.96B with short-term liabilities of ¥18.63B imply a cash coverage of 1.7x. Accounts receivable ¥13.99B (YoY +34.7%) indicates a notable expansion in working capital. Inventories ¥36.23B (YoY -18.9%) show improved inventory efficiency. [Investment Efficiency] Total Asset Turnover 0.468 (Revenue ¥42.0B ÷ Total Assets 89.8B yen), Return on Assets 5.0%. Asset efficiency declined from the prior year due to higher receivables. [Financial Soundness] Equity Ratio 79.3% (Net Assets 71.2B yen ÷ Total Assets 89.8B yen), Current Ratio 410.8% (Current Assets 76.68B yen ÷ Current Liabilities 18.66B yen), Quick Ratio 386.2%, indicating very strong liquidity. Interest-bearing debt ¥5.50B (Short-term borrowings ¥2.50B + Long-term borrowings ¥3.00B), Debt-to-Equity Ratio 0.26x, and Debt to Capital ratio 7.2% reflect a conservative capital structure. Note that short-term borrowings increased from ¥1.00B to ¥2.50B (+150%), lifting the short-term liabilities ratio to 45.5%, which warrants attention. Interest Coverage 129x (EBIT ¥6.43B ÷ Interest expense ¥0.05B) indicates minimal interest burden.
Although Operating Cash Flow is not disclosed, analyzing funding trends from balance sheet movements shows cash and deposits at ¥31.96B, slightly down from the same period last year, while accounts receivable rose significantly by YoY +¥3.60B (+34.7%), expanding working capital. Inventories decreased by -¥8.43B (-18.9%), suggesting better inventory efficiency, and accounts payable decreased slightly by YoY -¥0.03B; overall, the increase in receivables was the primary working capital cash absorption factor. Short-term borrowings increased by +¥1.50B to ¥2.50B, while long-term borrowings decreased by -¥1.50B to ¥3.00B, shifting the borrowing mix toward the short term. As a result, the short-term liabilities ratio rose to 45.5%, necessitating confirmation of the refinancing plan. With cash and deposits of ¥31.96B against short-term liabilities of ¥18.66B, short-term liabilities coverage stands at 1.7x, and with current assets of ¥76.68B, the Current Ratio of 410.8% indicates ample liquidity. On investing activities, property, plant and equipment increased modestly by YoY +¥0.24B and intangible assets by +¥0.06B, indicating no large-scale capital expenditures. The planned year-end dividend is ¥35, with total dividends of approximately ¥1.5B (4.21 million shares × ¥35), which is readily payable from the cash balance.
With Ordinary Income at ¥6.2B and Operating Income at ¥6.0B, the net increase from non-operating items is a modest approximately ¥0.2B. Non-operating income was ¥0.65B (details undisclosed), and after deducting non-operating expenses of ¥0.39B (including interest expense of ¥0.05B), it contributed to the Ordinary Income stage. Non-operating income accounts for about 1.5% of revenue, indicating a core operating-driven earnings structure. Extraordinary gains were ¥0.01B, with no extraordinary losses, and Income before income taxes of ¥6.21B did not change significantly from the Ordinary stage. Corporate taxes, etc. were ¥1.74B, putting the effective tax rate at approximately 28.0%, a standard level. Based on the balance sheet, the sharp increase in accounts receivable could pressure cash flows, making the cash backing of profits dependent on receivables collection. The reduction in inventories, improving working capital efficiency, contributes positively to earnings quality; however, if receivables management is inadequate, concerns may arise over the quality of earnings. At present, the decline in Operating Margin is the main qualitative issue, and the risk of sustained SG&A increases will influence profit durability.
[Position within Industry] (Reference Information; In-house research) The company belongs to the pharmaceuticals industry (pharma). Compared with the industry benchmark median for Q3 2025, profitability is exceptionally strong within the industry. Operating Margin of 14.2% (industry median -189.5%) and Net Profit Margin of 10.6% (industry median -191.3%) make the company’s continued profitability noteworthy within the sector. ROE 6.3% (industry median -48.8%) and ROA 5.0% (industry median -37.1%) are also in the upper tier. Revenue growth of +3.7% (industry median -10.8%) demonstrates an advantage versus the sector’s declining revenue trend. Financial soundness, while with a Current Ratio of 410.8% (industry median 6.10x, i.e., 610%) below the industry median, features an Equity Ratio of 79.3% (industry median 68.2%), placing capital adequacy in the upper tier. The Net Debt/EBITDA multiple is arithmetically low due to small debt, well below the industry median of 0.90, indicating a conservative level. While the pharmaceuticals industry often shows losses due to front-loaded R&D investment, the company maintains profitability, resulting in a favorable relative position within the industry. (Industry: Pharmaceuticals pharma, N=6 companies, comparison target: Q3 2025, source: in-house aggregation)
First, the coexistence of high profitability and financial soundness stands out. With a Gross Profit Margin of 47.4%, Operating Margin of 14.2%, and Equity Ratio of 79.3%, the company maintains a high value-added business model and a conservative capital structure. Second, trends in working capital management bear watching. While accounts receivable increased by +34.7% YoY, inventories decreased by -18.9%; progress in trade receivables management and inventory efficiency will drive future cash generation. Third, the increase in short-term borrowings and the rise in the short-term liabilities ratio are notable. The company is shifting toward reliance on short-term funding while reducing long-term borrowings, requiring confirmation of whether this reflects a change in funding policy or a temporary factor. Although cash coverage is sufficient, any maturity mismatch could surface refinancing risk. Fourth, the likelihood of achieving full-year guidance is in focus. Operating Income of ¥2.5B is needed in Q4, and the key will be whether SG&A control and revenue expansion can be achieved simultaneously. The dividend policy appears sustainable given current profit levels and cash balances, but progress in profit improvement remains a monitoring point.
This report is an earnings analysis document automatically generated by AI analyzing XBRL earnings release data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled in-house based on publicly available financial statements. Investment decisions are your own responsibility; consult a professional as needed before making any decisions.